Bionor provides update on funding
(Thomson Reuters ONE) -
BIONOR PHARMA ASA
STOCK EXCHANGE ANNOUNCEMENT
Bionor provides update on funding
(Oslo, Norway, 20 June 2016) Bionor Pharma ASA (OSE:BIONOR) announced today,
that the Board contemplates to launch a private placement of up to about NOK 70
million to be conducted within the end of this month. Further details on exact
timing and structure of this transaction will be disclosed when the result of a
pre-sounding phase has been concluded.
This announcement follows the stock exchange announcement as of 31 May 2016, in
which it was disclosed that the Board had decided that the company's long-term
funding initially would be covered by an equity offering to fund the company
through the following 6-12 months.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
Further information
Unni Hjelmaas, Acting CEO, +47 915 19 651, uh(at)bionorpharma.com
Jørgen Fischer Ravn, VP Investor Relations & Communications, +45 2030 3903,
jfr(at)bionorpharma.com
About Bionor
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its
proprietary therapeutic vaccine Vacc-4x in combination with other medicines
toward a functional HIV cure. The company believes it has first mover potential
based on clinical results to date and early adoption of now recognized clinical
strategy. In December 2015, Bionor announced that the HIV 'Shock & Kill' trial
REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by
reducing latent HIV reservoir and further demonstrated control of viral load.
Bionor currently retains full ownership rights to Vacc-4x, i.e., the upside
potential from partnering or licensing remains with the company's shareholders.
Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is
available at www.bionorpharma.com.
Bionor funding update:
http://hugin.info/131219/R/2021657/751069.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Bionor Pharma ASA via GlobeNewswire
[HUG#2021657]
Unternehmensinformation / Kurzprofil:
Datum: 20.06.2016 - 08:00 Uhr
Sprache: Deutsch
News-ID 478655
Anzahl Zeichen: 2710
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bionor provides update on funding"
steht unter der journalistisch-redaktionellen Verantwortung von
Bionor Pharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
